Scalable production of human iPS cell derived pancreatic beta cells using a bioreactor

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K18024
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: Kyoto University
• Principal Investigator: Shuhei Konagaya 京都大学, iPS細胞研究所, 特定研究員 (60770295)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: バイオリアクター / 膵島移植 / iPS細胞 / 分化誘導

Outline of Final Research Achievements

Islet transplantation has been performed as a treatment for insulin-dependent diabetes mellitus, but the shortage of transplanted islets has become a problem. The use of islets derived from ES / iPS cells is expected as a new cell source. Since a large amount of cells are required for the treatment of type I diabetes, it is indispensable to establish a three-dimensional culture method. The purpose of this study is to establish a three-dimensional culture method for large-scale production of iPS cell-derived islet cells.

Free Research Field

再生医療

Academic Significance and Societal Importance of the Research Achievements

Ⅰ型糖尿病の根本治療法として膵島移植が行われているが、膵島の不足が問題となっている。新たな細胞供給源としてES/iPS細胞から分化誘導した膵島の利用が期待されているが、十分な薬効を達成するためには大量な細胞を移植する必要があり、大量培養培養法の確立は必要不可欠である。本研究は、大量の移植可能な膵島細胞の調製を可能にする。